Literature DB >> 10390228

Activities of sordarins in murine histoplasmosis.

J R Graybill1, L Najvar, A Fothergill, R Bocanegra, F G de las Heras.   

Abstract

Sordarins are new antifungals which inhibit fungal protein synthesis by blocking elongation factor 2. Three compounds were evaluated in a murine model of histoplasmosis. Immune-competent mice were infected intravenously with 10(6) to 10(8) CFU of Histoplasma capsulatum yeast cells. Mice were treated either orally with sordarins or fluconazole from day 2 through 8 after infection or intraperitoneally with amphotericin B during the same period. Protection was measured by increased rates of survival for 30 days after infection or reduction of lung or kidney tissue counts 9 days after infection. All three of the antifungal drugs tested were protective compared with controls. Sordarins were effective at doses as low as 2 mg/kg of body weight/day. This novel class of drugs compared favorably with amphotericin B and fluconazole for the treatment of histoplasmosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390228      PMCID: PMC89349          DOI: 10.1128/AAC.43.7.1716

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Histoplasmosis in patients with AIDS: efficacy of maintenance amphotericin B therapy.

Authors:  D S McKinsey; M R Gupta; M R Driks; D L Smith; M O'Connor
Journal:  Am J Med       Date:  1992-02       Impact factor: 4.965

2.  Sordarins: A new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts.

Authors:  J M Domínguez; V A Kelly; O S Kinsman; M S Marriott; F Gómez de las Heras; J J Martín
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Ribosomal P-protein stalk function is targeted by sordarin antifungals.

Authors:  M G Gómez-Lorenzo; J F García-Bustos
Journal:  J Biol Chem       Date:  1998-09-25       Impact factor: 5.157

4.  Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.

Authors:  E Herreros; C M Martinez; M J Almela; M S Marriott; F G De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 5.  Histoplasmosis: recognition and treatment.

Authors:  J Wheat
Journal:  Clin Infect Dis       Date:  1994-08       Impact factor: 9.079

6.  Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.

Authors:  J Wheat; R Hafner; M Wulfsohn; P Spencer; K Squires; W Powderly; B Wong; M Rinaldi; M Saag; R Hamill; R Murphy; P Connolly-Stringfield; N Briggs; S Owens
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

7.  Histoplasmosis in the acquired immune deficiency syndrome.

Authors:  L J Wheat; T G Slama; M L Zeckel
Journal:  Am J Med       Date:  1985-02       Impact factor: 4.965

8.  Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome.

Authors:  P C Johnson; N Khardori; A F Najjar; F Butt; P W Mansell; G A Sarosi
Journal:  Am J Med       Date:  1988-08       Impact factor: 4.965

9.  Translation elongation factor 2 is part of the target for a new family of antifungals.

Authors:  L Capa; A Mendoza; J L Lavandera; F Gómez de las Heras; J F García-Bustos
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

10.  Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans.

Authors:  J M Domínguez; J J Martín
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

View more
  10 in total

1.  Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats.

Authors:  A Martinez; J Regadera; E Jimenez; I Santos; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Azasordarins: susceptibility of fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida spp. to GW 471558.

Authors:  M Cuenca-Estrella; E Mellado; T M Díaz-Guerra; A Monzón; J L Rodríguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Antifungal activities of R-135853, a sordarin derivative, in experimental candidiasis in mice.

Authors:  Yasuki Kamai; Masayo Kakuta; Takahiro Shibayama; Takashi Fukuoka; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding.

Authors:  P Aviles; C Falcoz; M J Guillén; R San Roman; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.

Authors:  P Aviles; A Pateman; R San Roman; M J Guillén; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Efficacies of sordarin derivatives GM193663, GM211676, and GM237354 in a murine model of systemic coccidioidomycosis. p6.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

7.  Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

Authors:  K V Clemons; M Martinez; L Calderon; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis.

Authors:  A Martinez; P Aviles; E Jimenez; J Caballero; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

9.  Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.

Authors:  A Martinez; S Ferrer; I Santos; E Jimenez; J Sparrowe; J Regadera; F G De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

10.  Antifungal activities and cytotoxicity studies of six new azasordarins.

Authors:  E Herreros; M J Almela; S Lozano; F Gomez de las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.